Home » Novartis Gene Therapy for Vision Loss Approved in EU
Novartis Gene Therapy for Vision Loss Approved in EU
The European Commission cleared Novartis’ Luxturna (voretigene neparvovec) for treatment of vision loss due to a genetic mutation in both copies of the RPE65 gene.
The treatment delivers a normal copy of the gene to retinal cells to restore vision using a modified version of a naturally-occurring adeno-associated virus.
The European Commission based its approval on a Phase 3 clinical trial showing vision improvement as early as 30 days following treatment. Vision improved for 90 percent of trial subjects.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May